Opportunity
Simpler Grants.gov #PAR-26-057
NIH Grant Forecast: Therapeutic Agent Characterization and Preclinical Efficacy Studies
Buyer
National Institutes of Health
Posted
February 25, 2026
Respond By
September 30, 2026
Identifier
PAR-26-057
NAICS
541715
This forecasted opportunity from the National Institutes of Health (NIH) supports research on therapeutic agent characterization and preclinical efficacy: - Government Buyer: - National Institutes of Health (NIH), including the National Institute of Neurological Disorders and Stroke, National Institute of Aging, and the NIH HEAL initiative - Products/Services Requested: - Research studies for pharmacodynamic, pharmacokinetic, and efficacy evaluation of therapeutic agents - Focus on small molecules or biologics for neurological disorders or non-opioid analgesic therapeutics with low addiction potential - Efficacy testing in validated in vivo models or New Approach Methodologies (NAMs) - Unique/Notable Requirements: - No specific OEMs or vendors; this is a grant for research, not a product procurement - Open to educational institutions, nonprofits, businesses, and government entities - No cost sharing or matching required - Place of Performance: - National Institutes of Health (federal office) - Period of Performance: - Forecasted project start date is July 1, 2027; duration not specified
Description
The National Institute of Neurological Disorders and Stroke, National Institute of Aging, the NIH Helping to End Addiction Long Term (HEAL) initiative, and other participating ICs seek to support applications to conduct pharmacodynamic, pharmacokinetic, and efficacy studies to demonstrate that the proposed therapeutic agent(s) have sufficient biological activity to warrant further development as therapeutics for disorders or diseases supported by participating ICs or for non-opioid analgesic therapeutics with little or no addiction liability as a part of the NIH HEAL initiative. Therapeutic agents include small molecules or biologics. Efficacy testing can be conducted in validated in vivo models and/or validated New Approach Methodologies (NAMs) as appropriate. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.